Beth Seidenberg Buys 133,333 Shares of Kyverna Therapeutics (NASDAQ:KYTX) Stock

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Director Beth Seidenberg purchased 133,333 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were bought at an average cost of $7.50 per share, with a total value of $999,997.50. Following the completion of the acquisition, the director owned 869,317 shares of the company’s stock, valued at approximately $6,519,877.50. This trade represents a 18.12% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kyverna Therapeutics Stock Performance

KYTX traded up $1.10 during trading on Monday, hitting $8.29. The stock had a trading volume of 2,441,526 shares, compared to its average volume of 630,496. The firm has a market capitalization of $363.07 million, a P/E ratio of -2.24 and a beta of 3.66. Kyverna Therapeutics, Inc. has a twelve month low of $1.78 and a twelve month high of $13.67. The company’s 50-day moving average price is $7.39 and its 200 day moving average price is $5.21.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Wednesday, November 12th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.12. As a group, equities analysts expect that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kyverna Therapeutics

Large investors have recently added to or reduced their stakes in the business. Insight Holdings Group LLC boosted its stake in Kyverna Therapeutics by 8.3% during the first quarter. Insight Holdings Group LLC now owns 989,054 shares of the company’s stock valued at $1,909,000 after buying an additional 76,139 shares in the last quarter. TD Asset Management Inc boosted its position in shares of Kyverna Therapeutics by 179.5% during the 2nd quarter. TD Asset Management Inc now owns 252,196 shares of the company’s stock valued at $774,000 after purchasing an additional 161,954 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Kyverna Therapeutics in the 2nd quarter worth approximately $129,000. Ethic Inc. acquired a new position in shares of Kyverna Therapeutics in the 2nd quarter worth approximately $56,000. Finally, Phoenix Wealth Advisors bought a new stake in shares of Kyverna Therapeutics in the 2nd quarter worth approximately $32,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company lifted their price target on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Morgan Stanley set a $33.00 price target on Kyverna Therapeutics in a research note on Monday, December 15th. HC Wainwright lifted their target price on shares of Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Wall Street Zen raised shares of Kyverna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Monday, December 15th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.67.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.